Načítá se...
Separation of outer retinal layers secondary to selumetinib
New therapeutic agents targeting the mitogen-activated protein (MAP) kinase pathway, including MEK inhibitors, are currently being evaluated in phase 1 and 2 clinical trials for pediatric brain tumors. Ophthalmologic side effects from MEK inhibitors have previously only been reported in adults and i...
Uloženo v:
| Vydáno v: | J AAPOS |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4912405/ https://ncbi.nlm.nih.gov/pubmed/27108842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaapos.2016.01.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|